Oruka Therapeutics (ORKA) Misses Q4 EPS by 49c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures subdued as investors weigh earnings, oil prices
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil prices hit fresh 6-week highs on renewed Middle East tensions
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Stifel Reiterates Buy Rating on Oruka Therapeutics (ORKA)
March 7, 2025 7:41 AM ESTStifel analyst Alex Thompson reiterated a Buy rating and $49.00 price target on Oruka Therapeutics (NASDAQ: ORKA)
The analyst comments "We are reiterating our Buy rating following ORKA's 4Q24 update. We think ORKA is well-positioned to drive continued innovation in the psoriasis market (and beyond)... More
